13 An important problem in evolution is identifying the genetic basis of how different species adapt 14 to similar environments. Understanding how various bacterial pathogens evolve in response to 15 antimicrobial treatment is a pressing example of this problem, where discovery of molecular 16 parallelism could lead to clinically useful predictions. Evolution experiments with pathogens in 17 environments containing antibiotics combined with periodic whole population genome 18 sequencing can be used to characterize the evolutionary dynamics of the pathways to 19 antimicrobial resistance. We separately propagated two clinically relevant Gram-negative 20 pathogens, Pseudomonas aeruginosa and Acinetobacter baumannii, in increasing 21 concentrations of tobramycin in two different environments each: planktonic and biofilm.
Introduction
system has been shown to regulate expression of genes responsible for coordinating the antibiotic stress response, suggesting an indirect link between the nitrogen phosphotransferase and ptsP appear to be most fit in the presence of TOB across species and environments.
143
To clarify the specific effects of these mutations in TOB resistance, isogenic mutants 144 were obtained by isolating clones from evolved P. aeruginosa populations and genotyping them 145 by WGS. Two isogenic fusA1 clones (N592I, Q678L), and ptsP clones (D14bp,1296-1309, were 2-4x more resistant to including amikacin, gentamycin, and tigecycline than the ancestor.
suggesting specificity to TOB resistance. While species-specific mutations did occur in cyoA, 152 cyoB, orfK, orfH, orfL, and orfN as discussed below, the parallel evolution of mutations in fusA1 153 and ptsP across A. baumannii and P. aeruginosa indicate that regardless of genetic 154 background, these are among relatively few loci in which mutations can jointly increase TOB 155 resistance and fitness in these conditions.
156
Environment-associated adaptations to TOB selection but only one biofilm population contained a ptsP mutation at day twelve. Rather, these biofilm 164 populations of P. aeruginosa biofilm populations frequently acquired mutations in orfK, orfH, 165 orfL, or orfN genes (subsequently referred to jointly as orfKHLN), encoding O antigen 166 biosynthesis enzymes, whereas this locus was only mutated in one of the planktonic 167 populations (Burrows et al., 1996; Rocchetta et al., 1999) . A mutation in orfK also occurred in a 168 population with biofilm but no TOB selection, suggesting that orfKHLN mutations may be 169 beneficial in both biofilm and TOB selection alone, but most beneficial in the combination of 170 these conditions (Figure 2 ).
171
The genetic targets of resistance were more consistent in A. baumannii populations 172 treated with TOB, with fusA1 and ptsP mutations reaching similar frequencies in both biofilm 173 and planktonic treatments by the end of the experiment. However, mutations in cyoA and cyoB 174 (subsequently referred to jointly as cyoAB), encoding components of the electron transport 175 chain, were associated with only biofilm lineages ( Figure 2) (Ibacache-Quiroga et al., 2018) .
176
Together, the mutations enriched in biofilm lineages (orfKHLN, cyoAB) indicate that lifestyle 177 may influence the identity of targets under selection by TOB or their frequency (fusA1, ptsP).
178
The parallel evolution of mutations in four genes associated with O antigen biosynthesis 179 within and between populations strongly suggests that the outer membrane may be altered in 180 response to TOB and biofilm selection in P. aeruginosa (Burrows et al., 1996; Tognon et al., 181 2017; Wong et al., 2012) . Experiments in strain PAO1 have shown that loss of B band O 182 antigen is associated with aminoglycoside resistance by increasing impermeability and reducing 183 binding affinity to the outer membrane (Bryan et al., 1984; Kadurugamuwa et al., 1993) .
184
Similarly, populations of A. baumannii evolved with TOB and biofilm selection acquired 185 mutations in the cyoAB operon, encoding components of the electron transport chain. Mutations 186 in electron transport chain components have previously been associated with resistance to in the two species propagated in this experiment evolved mutations in different genetic loci (affecting LPS biosynthesis genes in P. aeruginosa and electron transport chain components in Population-genetic dynamics of TOB resistance evolution
194
We used longitudinal population sequencing of three lineages per treatment to 195 determine effects of species and environment on the population-genetic dynamics of adaptation 196 to the antibiotic. The trajectories of allele frequencies (shown in Figure S4 ) were used to predict 197 mutation linkage and hence the assembly and dynamics of genotypes, which are represented 198 by Muller plots (Figure 3 , see methods). Genotype frequency is represented by the breadth of 199 shading with colors corresponding to the putative driver mutations of that genotype. In all 200 lineages, regardless of environment, mutations in fusA1 were detected at either 0.5x MIC or 201 1.0x MIC and subsequently rose to high frequencies (Figure 3, red) . Their rapid rise in 202 frequency in the first few days of the experiment suggests that fusA1 mutations were the fittest 203 contending mutations at subinhibitory concentrations of TOB. Lineages with different SNPs in 204 the fusA1 gene coexisted in some populations for the duration of the experiment, suggesting 205 that different fusA1 genotypes had similar fitness in increasing TOB. While a single, selected 206 nonsynonymous fusA1 mutation was presumably sufficient for survival to the end of the 207 experiment due to the presence of clones with no other mutations at day twelve (Supplementary 208 Data), secondary mutations were selected in these genotypes in the genes discussed 209 previously (ptsP, orfKHLN, and cyoAB, Figure 3) . A. baumannii populations tended to become 210 dominated by fusA1+ptsP genotypes, but biofilm populations also selected cyoAB mutants prior 211 to day nine (up to 2x MIC) that were outcompeted by a fusA1+ptsP genotype at 4x MIC TOB. mutants on a fusA1 background. These evolutionary dynamics demonstrate that following initial 216 selection of a fusA1 mutation, selection favored secondary mutations particular to lifestyle and 217 species.
218
Parallelism of aminoglycoside resistance mechanisms across species and clinical 219 isolates 220
The repeated evolution of fusA1 and ptsP mutations in both P. aeruginosa and A.
221
baumannii suggested that these mutations may provide a general mechanism of TOB 222 resistance across diverse species. We tested this hypothesis by searching published datasets 223 and genomes for fusA1, ptsP, cyoA, and cyoB mutations (Methods). Mutations in fusA1 were 224 found in several different species including E. coli, S. typhimurium, and S. aureus (Ibacache-225 Quiroga et al., 2018; Jahn et al., 2017; Johanson and Hughes, 1994; Kim et al., 2014; Mogre et 226 al., 2014; Norström et al., 2007) , and all laboratory studies reported these mutations either in 227 response to aminoglycoside selection or as a direct cause of aminoglycoside resistance ( Figure   228 4). Mutations in cyoA and cyoB were also found in E. coli and S. typhimurium in these 229 experiments (Ibacache-Quiroga et al., 2018; Jahn et al., 2017; Johanson and Hughes, 1994) .
230
Multiple sequence alignment of these genes across species revealed that fusA1 mutations were 231 localized to two primary regions across all species and were primarily nonsynonymous SNPs, 232 and eight positions exhibit amino acid-level parallelism across species ( Figure 4 , Table S1 , 233 Figure S5 ) (Wattam et al., 2017) . In this dataset, mutations occurred at positions with identical 234 amino acids across species more frequently than expected by chance for fusA1 (c 2 = 11.58, df = 235 1, p = 0.0006), ptsP (c 2 = 4.37, df = 1, p = 0.03652), and cyoA (c 2 = 3.89, df = 1, p = 0.0486).
236
The parallel evolution of fusA1 mutations across species and environments demonstrates the 237 potential utility of this gene as a predictive marker of aminoglycoside resistance.
238
To examine if the precise mutations found in our in vitro study were also found in clinical patients who had likely been treated with aminoglycosides like TOB (Bolard et al., 2017; Chung Although it is not possible to distinguish aminoglycoside selection as the driver of these 244 mutations in a clinical setting, the selection of mutations in these genes in our evolution 245 experiment and the increased resistance that these mutations have the same effect in vivo.
246
Taken together, the parallel evolution of mutations in these genes in clinical isolates of a wide 247 range of species indicates they commonly contribute to aminoglycoside resistance in diverse 248 environments, including the cystic fibrosis respiratory tract. 
262
Because antibiotics often induce cell killing by targeting conserved domains of proteins 263 involved in essential cell processes, there is potential for mutations in these genes to confer 264 resistance in diverse bacterial strains and species. However, many have appreciated that 265 epistatic interactions stemming from differing genetic backgrounds could limit parallel evolution of resistance mechanisms (Breen et al., 2012; MacLean et al., 2010; Ward et al., 2009) . In spite 267 of the many genetic differences between A. baumannii and P. aeruginosa -the latter genome 268 much larger and containing dozens of additional putative resistance loci -we identified parallel 269 mutations in fusA1 and ptsP in response to tobramycin selection, a largely unknown 270 combination of mutations conferring high fitness and resistance. Furthermore, we found amino 271 acid-level parallelism of fusA1 mutations associated with aminoglycoside resistance, including 272 kanamycin, gentamycin, and amikacin, across diverse species including E. coli, S. typhimurium, 273 and S. aureus (Figure 4 , Figure S5 ). Our finding that fusA1 mutations repeatedly evolve in 274 clinical P. aeruginosa isolates from different strain types and host conditions further supports the 275 notion that these mutations can arise in a range of genetic backgrounds and environments, and 276 we predict that fusA1 mutations may be considerably more prevalent following antibiotic therapy 277 than previously appreciated. These fusA1 mutations also produced cross resistance to other The extent of parallelism in molecular evolution in these experiments is surprising and its mutations across species also suggests that these mutations may have relatively low epistatic 318 interactions with the genetic background of the strain. Predictability may be more challenging if 319 epistatic effects of resistance alleles are greater.
320
Several studies of experimentally evolved microbial populations have demonstrated a 321 general "rule of declining adaptability", whereby beneficial mutations produce diminishing fitness 322 benefits as a population becomes better adapted to its environment (Kryazhimskiy et al., 2014;  323 Wang et al., 2016) . These studies have experimentally determined that populations exhibit 324 global diminishing returns epistasis, in which the relative fitness level of different strains in an 325 environment influences the fitness effect of a given mutation more than the specific genetic 326 differences between the strains. Our study is consistent with this model: A. baumannii and P.
327
aeruginosa are highly unfit in the TOB concentrations utilized in this study and exhibit similar 328 benefits from fusA1 and ptsP mutations despite genetic differences in the ancestral genotypes.
329
Theory suggests that if these strains were more fit in these conditions, for example if they were 330 more resistant to the TOB concentrations in which they are growing, fusA1 and ptsP mutations 331 may be less beneficial and thus evolution less predictable. In other antibiotic or species 332 combinations, it remains to be seen if effects of resistance mutations are heavily skewed toward 333 a few that are most fit and whether subsequent resistance mutations exhibit diminishing returns 334 that weaken selection and increase variation among populations.
335
In this study we have identified gene and nucleotide level parallelism of molecular Figure S1 ). Clones were measured by the same procedure with 391 the exception that freezer stocks were streaked for isolation and MIC assays were performed 392 using an isolated colony. MICs of other ribosome-targeting antibiotics for the fusA1 and ptsP isogenic mutants were performed using Sensititre plates according to manufacturer they are present at least 5% frequency within the population and are in at least 2 reads from 420 each strand. The A. baumannii ATCC 17978-mff genome (NZ_CP012004) and plasmid 421 NZ_CP012005 sequences were downloaded from RefSeq. Two additional plasmids were found 422 to exist in our working strain and were added to this reference genome: NC009083 and 423 NC_009084. The P. aeruginosa UCBPP-PA14 genome was downloaded from RefSeq 424 (NC_008463). Mutations were removed if they were also found in the ancestor's sequence 425 when mapped to the reference genome. Mutations that did not reach at least 25% cumulative 426 frequency across all populations at all timepoints were removed, and mutations were also 427 manually curated to remove biologically implausible mutations. A mutation was determined 428 biologically implausible if it occurred either i) at trajectories that were not possible given the 429 trajectories of the putative driver mutations, ii) at only the ends of reads, only reads with many 430 other mutations, or at only low coverage (<10 reads), indicating poor read mapping at that 431 region. When high-quality mutations in loci related to the putative driver loci or ribosome 432 machinery were reported in New Junction Evidence by breseq, these mutations were also 433 included in the analysis. Mutations fitting these criteria included mutations to 23S rRNA in P. 
453
Mutations in these genes in clinical isolates were found by searching for whole genome 454 sequencing studies of P. aeruginosa isolates from cystic fibrosis patients that reported these 455 mutations. We tested whether the SNPs identified in each of these genes occur in conserved 456 positions more frequently than expected considering the frequency of conserved positions within 457 the genes using a Pearson's Chi-squared test ( Figure S5 ).
459
Acknowledgments and Funding Sources planktonic growth through a daily 1:100 dilution or biofilm growth through a daily bead transfer 474 that forces cells to undergo the entire biofilm lifecycle of attachment, growth, dispersion and 475 reattachment every 24 hours as described in previous work (Poltak and Cooper, 2011) . C).
476
Tobramycin resistance level relative to the ancestral clone for three randomly chosen Figure 1 . Method of long-term experimental evolution in biofilms in which genetic and ecological conditions can be reconstituted from archived samples. Each day, cells must attach to a plastic bead, grow in a biofilm, and disperse to a new bead.
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